7201 results for "canc*"

in 18.53 milliseconds.

• The identification of genetic vulnerabilities in head and neck cancers for the development of novel therapies (2020-01-15)

  CRISPR/Cas9 lethality screens in a set of Asian head and neck cancer cell lines to identify novel targets. . This dataset contains all the data available for this study on 2020-01-15.

  Dataset EGAD00001005784

• Tumour sample for patient SA596

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA596

  Dataset EGAD00001009201

• Normal sample for patient SA212

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA212

  Dataset EGAD00001009546

• Tumour sample for patient SA229

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA229

  Dataset EGAD00001009534

• Lung cancer and non-cancerous plasma cfDNA samples

  The dataset contains 90 lung cancer and 5 non-cancerous lung lesion plasma cfDNA samples collected in EDTA blood collection tubes. Shallow WGS was performed on an Illumina Novaseq S4 PE150bp. Samples are provided as raw reads without any prior processing.

  Dataset EGAD00001008666

• Normal sample for patient SA225

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA225

  Dataset EGAD00001009549

• Normal sample for patient SA230

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA230

  Dataset EGAD00001009553

• Genome and transcriptome sequence data from a poorly differentiated adenocarcinoma more consistent with metastatic melanoma patient

  Genome and transcriptome sequence data from a poorly differentiated adenocarcinoma more consistent with metastatic melanoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study

  Dataset EGAD00001005831

• Normal sample for patient SA290

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA290

  Dataset EGAD00001009564

• Normal sample for patient SA271

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA271

  Dataset EGAD00001009559

• Normal sample for patient SA284

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA284

  Dataset EGAD00001009562

• Normal sample for patient SA278

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA278

  Dataset EGAD00001009561

• Normal sample for patient SA285

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA285

  Dataset EGAD00001009563

• Normal sample for patient SA294

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA294

  Dataset EGAD00001009565

• Somatic mutation rates scale with lifespan across mammals

  The rates and patterns of somatic mutation in normal tissues are largely unknown outside of humans. Comparative analyses can shed light on the diversity of mutagenesis across species and on long-standing hypotheses regarding the evolution of somatic mutation rates and their role in cancer and ageing. Here, we used whole-genome sequencing of 208 intestinal crypts from 56 individuals to study the landscape of somatic mutation across 16 mammalian species. We found somatic mutagenesis to be dominated by seemingly endogenous mutational processes in all species, including 5-methylcytosine deamination and oxidative damage. With some differences, mutational signatures in other species resembled those described in humans, although the relative contribution of each signature varied across species. Remarkably, the somatic mutation rate per year varied greatly across species and exhibited a strong inverse relationship with species lifespan, with no other life-history trait studied displaying a comparable association. Despite widely different life histories among the species surveyed, including ~30-fold variation in lifespan and ~40,000-fold variation in body mass, the somatic mutation burden at the end of lifespan varied only by a factor of ~3. These data unveil common mutational processes across mammals and suggest that somatic mutation rates are evolutionarily constrained and may be a determinant of lifespan.

  Dataset EGAD00001008032

• Genome and transcriptome sequence data from a metastatic melanoma patient

  Genome and transcriptome sequence data from a metastatic melanoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study

  Dataset EGAD00001005851

• Normal sample for patient SA296

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA296

  Dataset EGAD00001009566

• Mutational landscape of normal epithelial cells in Lynch Syndrome patients

  Lynch Syndrome (LS) is an autosomal dominant disease conferring a high risk of colorectal cancer due to germline heterozygous mutations in a DNA mismatch repair (MMR) gene. Although cancers in LS patients show elevated somatic mutation burdens, information on mutation rates in normal tissues and understanding of the trajectory from normal to cancer cell is limited. Here we whole-genome sequenced 152 crypts from normal and neoplastic epithelial tissues from LS patients. In normal tissues the repertoire of mutational processes and mutation rates were similar to those found in wild type individuals. A morphologically normal colonic crypt with an increased mutation burden and mutational signatures consistent with MMR deficiency was identified, which may represent a very early stage of LS pathogenesis. Phylogenetic tress of tumour crypts indicated that the most recent ancestor cell of each tumour was already MMR deficient and had experienced multiple clonal evolution cycles. This study demonstrates the genomic stability of epithelial cells with heterozygous germline MMR gene mutations and highlights important differences in the pathogenesis of LS from other colorectal cancer predisposition syndromes.

  Dataset EGAD00001008092

• Genome and transcriptome sequence data from a cecum adenocarcinoma patient

  Genome and transcriptome sequence data from a cecum adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study

  Dataset EGAD00001005895

• Normal sample for patient SA399

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA399

  Dataset EGAD00001009567

• Normal sample for patient SA409

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA409

  Dataset EGAD00001009569

• Tumour sample for patient SA288

  Whole genome sequencing of tumour sample for triple negative breast cancer patient SA288

  Dataset EGAD00001009578

• Normal sample for patient SA718

  Whole genome sequencing of normal sample for triple negative breast cancer patient SA718

  Dataset EGAD00001009582

• Genome and transcriptome sequence data from a pancreatic ductal adenocarcinoma patient

  Genome and transcriptome sequence data from a pancreatic ductal adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study

  Dataset EGAD00001005904

• Genome and transcriptome sequence data from a gastroesophageal junction adenocarcinoma patient

  Genome and transcriptome sequence data from a gastroesophageal junction adenocarcinoma patient, generated as part of the BC Cancer Agency's Personalized OncoGenomics (POG) study

  Dataset EGAD00001005910